Influence of histamine, cimetidine and pyrilamine on naloxone-induced jumping in morphine-dependent mice. 2003

Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran. zarinmr@ams.ac.ir

In the present study, the effects of histamine on naloxone-induced jumping in the presence or absence of adrenoceptor or acetylcholine receptor antagonists in morphine-dependent mice were examined. In these experiments, the drugs were used before s.c. injection of naloxone (2 mg/kg), to test their effects on the expression of jumping. The i.c.v. administration of histamine (5-20 microg/mouse) 15 min before naloxone injection decreased the number of jumps in mice. When the histamine H(2) receptor antagonist, cimetidine (5-20 mg/kg), and the histamine H(1) receptor antagonist, pyrilamine (5-20 mg/kg), were administered i.p. to morphine-dependent mice, only cimetidine enhanced the jumping behaviour. Administration of cimetidine (20 mg/kg, i.p.), 30 min, of the beta-adrenoceptor antagonist, propranolol (2.5-10 mg/kg, i.p.), 15 min but not of pyrilamine (20 mg/kg, i.p.), 30 min before naloxone injection, decreased the histamine effect. The i.p. administration of an acetylcholine receptor antagonist, atropine (5 and 10 mg/kg, i.p.), the alpha(1)-adrenoceptor antagonist, prazosin (0.5, 1 and 2 mg/kg, i.p.), and alpha(2)-adrenoceptor antagonist, yohimbine (0.5, 1 and 2 mg/kg, i.p.), 15 min before naloxone injection, had no effect on the histamine response. Single administration of propranolol, atropine or prazosin decreased, while yohimbine increased the naloxone-induced jumping. It is concluded that the histamine H(2) receptor mechanism may be involved in the influence of histamine on the expression of naloxone-induced jumping in morphine-dependent mice.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009021 Morphine Dependence Strong dependence, both physiological and emotional, upon morphine. Morphine Abuse,Morphine Addiction,Abuse, Morphine,Addiction, Morphine,Dependence, Morphine
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011738 Pyrilamine A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies. Mepyramine,Pyranisamine,Anthisan,Boots Bite & Sting Relief,Kriptin,Mepyramine Maleate,Pyrilamine Maleate,Maleate, Mepyramine,Maleate, Pyrilamine

Related Publications

Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
April 1974, European journal of pharmacology,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
February 1996, European journal of pharmacology,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
October 1986, Archives internationales de pharmacodynamie et de therapie,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
September 1999, European journal of pharmacology,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
January 1975, International pharmacopsychiatry,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
September 2002, European journal of pharmacology,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
January 1986, Journal of ocular pharmacology,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
February 1999, Pharmacology, biochemistry, and behavior,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
March 1989, European journal of pharmacology,
Mohammad Reza Zarrindast, and Elham Assadi, and Shahrbano Oryan, and Anahita Torkaman-Boutorabi, and Mousa Sahebgharani
November 1976, Research communications in chemical pathology and pharmacology,
Copied contents to your clipboard!